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early hospital readmissions after 
ABo- or HLA- incompatible living 
donor kidney transplantation
Juhan Lee1, Deok Gie Kim1, Beom seok Kim2,3, Myoung soo Kim1,3, soon Il Kim1,3, 
Yu seun Kim1,3 & Kyu Ha Huh1,3
early hospital readmission (eHR) after kidney transplantation (Kt) is associated with adverse outcomes 
and significant healthcare costs. Despite survival benefits, ABO- and HLA-incompatible (ABOi and HLAi) 
KTs require desensitization and potent immunosuppression that increase risk of EHR. However, little 
data exist regarding EHR after incompatible KT. We defined EHR as admission for any reason within 30 
days of discharge from the index hospitalization. Patients who underwent living donor KT from 2010–
2017 were classified into one of three groups (control, ABOi KT, or HLAi KT). Our study included 732 
patients, 96 (13.1%) of who experienced EHR. HLAi KT patients had a significantly higher incidence of 
EHR than other groups (26.6%; P < 0.001). In addition, HLAi KT (HR, 2.26; 95% CI, 1.35–3.77; P = 0.002) 
and advanced age (≥60 years) (HR, 1.93; 95% CI, 1.20–3.12; P = 0.007) were independent risk factors 
for EHR. Patients with EHR showed 1.5 times and 3 times greater risk of late hospital readmission and 
death-censored graft loss, respectively, and consistently exhibited inferior renal function compared 
to those without EHR, regardless of immunologic incompatibilities. We recommend that KT recipients 
experiencing eHR or its risk factors be managed with extreme care due to their increased susceptibility 
to adverse outcomes.
Kidney transplantation (KT) is the treatment of choice for end-stage renal disease patients1. However, thousands 
of patients remain on the waiting list because of ABO or HLA incompatibilities despite healthy and willing liv-
ing donors2. These patients generally experience prolonged waiting times and are less likely to find a suitable 
donor than other potential recipients. Fortunately, desensitization protocols and advanced antibody detection 
techniques now enable successful KTs across immunologic barriers3,4, and although outcomes of incompatible 
KTs are often inferior to those of compatible KTs, these transplants offer greater survival benefit compared with 
remaining on dialysis5.
Early hospital readmission (EHR), defined as readmission within 30 days of initial discharge, increases health-
care cost and is strongly associated with morbidity6. Despite recent progress, EHR is common after KT7,8 and is 
associated with adverse outcomes such as late readmission, graft loss, and mortality9–12. Prior studies identified 
several risk factors for EHR including age, sex, comorbidities, and length of stay (LOS)10,13–15. However, each KT 
recipient carries distinct immunologic risks that also significantly affect the postoperative course16. For exam-
ple, patients with ABO or HLA incompatibility (ABOi or HLAi) require potent immunosuppression, including 
desensitization, and are at higher risk of rejection or infectious complications after successful KT17–19. Therefore, 
immunologic status should be considered when monitoring transplant recipients.
Due to a continual lack of organs and a rapid increase of end-stage renal disease patients, occurrence of 
incompatible KT will inevitably rise as well2,20. Understanding the burdens, risks, and outcomes related of EHR 
in incompatible KT patients is important for their long-term care. Therefore, the goals of this study involved 
quantifying the incidence of EHR and evaluating its relationships with graft survival, late hospital readmission, 
and renal function after ABOi and HLAi KT.
1Department of transplantation Surgery, Severance Hospital, Yonsei University Health System, Seoul, Republic 
of Korea. 2Department of nephrology, Severance Hospital, Yonsei University Health System, Seoul, Republic of 
Korea. 3Research institute for transplantation, Yonsei University college of Medicine, Seoul, Republic of Korea. 
correspondence and requests for materials should be addressed to K.H.H. (email: khhuh@yuhs.ac)
Received: 26 November 2018
Accepted: 30 January 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:3246  | https://doi.org/10.1038/s41598-019-39841-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
Results
Study population. This retrospective analysis was conducted on all consecutive living donor KT between 
January 2010 and December 2017 at Severance Hospital. A total of 732 patients who met the inclusion/exclusion 
criteria were included in the study (Fig. 1). Of these patients, 158 underwent ABOi KT and 79 underwent HLAi 
KT (14 combined HLAi and ABOi KT).
Demographic and baseline clinical characteristics. Patient characteristics are summarized in Table 1. 
We found no significant differences in body mass index (BMI), dialysis duration, and history of diabetes among 
the three KT groups. However, the proportion of female recipients and re-transplant cases were significantly 
higher in the HLAi KT group than in the other groups. HLAi KT patients were significantly older and had higher 
number of HLA mismatches than those in other groups. Of HLAi KT patients, 26 (32.9%) exhibited a positive 
complement-dependent cytotoxicity (CDC) crossmatch, and 53 (67.1%) had a positive flow cytometric cross-
match. Patients with CDC crossmatch positive had significantly higher mean fluorescence intensity than those 
with flow cytometric positive (9031 ± 5912 vs. 5867 ± 4694, P = 0.013). A total of 26 patients (33%) had DSA 
against both class I and class II. Twenty-one recipients (26.9%) had class I DSA and 31 (39.7%) had class II DSA. 
Of ABOi KT patients, 122 (77.2%) had low titer of anti-A/B (≤1:64) and 36 (22.8%) had high titer of anti-A/B 
(≥1:128). We observed no significant differences in donor characteristics among the groups, with the exception 
of a lower proportion of female donors in the HLAi KT group. The use of anti-thymocyte globulin for induction 
was significantly more common for patients in the HLAi KT group than for those in the ABOi KT and control 
groups. Mean serum tacrolimus concentrations during the entire study period were similar in the three groups 
(P > 0.05). The median duration of the follow-up period was 45 months.
Index hospitalization. Clinical outcomes during index hospitalizations are shown in Table 2. During the 
pre-KT hospital stay, we performed thorough medical, immunological, and psychological evaluation. ABOi KT 
and HLAi KT patients had significantly longer pre-KT hospital stays than control group patients (P < 0.001), 
Figure 1. Study flow diagram.
Controls 
(n = 495)
ABOi KT 
(n = 158)
HLAi KT 
(n = 79) P-value
Female 188 (38.0%) 53 (33.5%) 63 (79.7%) <0.001
Age (years) 46.0 ± 12.1 46.1 ± 11.3 50.1 ± 9.8 0.014
BMI (kg/m2) 22.7 ± 3.4 22.7 ± 3.4 22.3 ± 2.7 0.561
Re-transplant 26 (5.3%) 11 (7.0%) 17 (21.5%) <0.001
History of diabetes 118 (23.8%) 42 (26.6%) 21 (26.6%) 0.723
History of CVD 16 (3.2%) 15 (9.5%) 7 (8.9%) 0.003
Hepatitis C virus 6 (1.2%) 2 (1.3%) 1 (1.3%) 0.955
HLA mismatch 3.2 ± 1.6 3.5 ± 1.6 3.8 ± 1.3 0.004
Dialysis duration 15.6 ± 33.5 13.6 ± 30.8 18.7 ± 27.3 0.516
Female donor 288 (58.2%) 100 (63.3%) 33 (41.8%) 0.006
Donor age (years) 42.1 ± 11.7 42.7 ± 10.8 42.4 ± 12.3 0.845
Donor BMI (kg/m2) 23.1 ± 2.7 23.1 ± 2.6 23.5 ± 2.4 0.492
Induction agents <0.001
  Basiliximab 488 (98.6%) 152 (96.2%) 28 (35.4%)
  ATG 7 (1.4%) 6 (3.8%) 51 (64.6%)
Follow-up (months) 45.0 (22,71) 46.5 (21.8, 70) 42.0 (26,59) 0.376
Table 1. Demographic and baseline clinical characteristics of participants.
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while the length of post-KT hospital stays in the HLAi KT group was significantly longer than the stay lengths of 
both ABOi KT and control patients (P < 0.001).
The incidence of delayed graft function was significantly higher in the HLAi KT group than that of other 
groups (3.4% in controls, 1.9% in ABOi KTs, and 8.9% in HLAi KTs; P < 0.001). Fifty-four patients developed 
biopsy-proven acute rejection during their index hospitalization for KT [41 antibody-mediated rejection (AMR) 
and 13 T-cell medicated rejection (TCMR)]. The median time from KT to biopsy was 8 days [interquartile range 
(IQR), 5–14 days]. HLAi KT patients exhibited significantly higher rates of AMR than ABOi KT and control 
groups (19.0% in HLAi KTs, 4.4% in ABOi KTs, and 3.8% in controls, respectively; P < 0.001). We found no sig-
nificant differences among the groups for TCMR incidence (P = 0.507). No patients died or experienced allograft 
loss during index hospitalization for KT.
Parameters of EHR. During the study period, 96 recipients experienced EHR (13.1%). As shown in Fig. 2, 
55 patients (11.1%) in the control group, 20 patients (12.7%) in the ABOi KT group, and 21 patients (26.6%) in 
the HLAi KT group experienced EHR (P = 0.002). The median time from transplant discharge to EHR was 13 
days (IQR, 6–22 days) with no significant differences seen among groups (P = 0.154). The median LOS for EHR 
was 8 days (IQR, 4–15 days) with a maximum of 149 days. Median LOS were similar in the control (8 days) and 
ABOi KT groups (7.5 days) but significantly longer in the HLAi KT group (12 days, P = 0.034).
The leading causes of EHR were infection (35.4%), creatinine elevation (30.2%), and surgical complication 
(10.4%) (Table 3). The proportion of infection was significantly higher in the HLAi KT group (52.4%) than in the 
other groups (30.9% in control and 30% in ABOi KT group, P = 0.009).
Thirty-three patients underwent biopsies for acute allograft dysfunction during their EHR (n = 13, TCMR 
and n = 10, AMR). Most cases of rejection in the control group were diagnosed as TCMR. In contrast, AMR was 
found in 12.5%, 27.3%, and 83.3% of control, ABOi KT, and HLAi KT biopsied patients, respectively. There was 
no mixed rejection during EHR.
Outcomes and risk factors of EHR. During EHR, one patient died due to gastrointestinal bleeding, and 
another patient experienced graft loss due to refractory TCMR. As shown in Fig. 3, death-censored graft survival 
rates were worse for KT patients with EHR than those without EHR (86.5% vs. 94.8% at 5 years; P < 0.001) but 
were comparable for control, ABOi KT, and HLAi KT groups (94.0%, 91.9%, and 91.6% at 5 years, respectively, 
P = 0.601). The 5-year patient survival rates were 97.4% in patients with EHR compared to 96.1% in those without 
Controls 
(n = 495)
ABOi KT 
(n = 158)
HLAi KT 
(n = 79) P-value
Length of stay (days)
  Pre-KT 8 [8, 8] 9 [8, 10.25] 10 [8, 14] <0.001
  Post-KT 14 [13,16] 15 [14, 17] 16 [14, 24] <0.001
Numbers of pre-KT plasmapheresis — 4.0 ± 2.3 4.3 ± 1.8 0.329
Delayed graft function, n (%) 17 (3.4%) 3 (1.9%) 7 (8.9%) 0.024
Biopsy-proven acute rejection, n (%)
  Antibody-mediated rejection 19* (3.8%) 7 (4.4%) 15 (19.0%) <0.001
  T-cell mediated rejection 10 (2.0%) 2 (1.3%) 1 (1.3%) 0.507
Mean eGFR at discharge 68.4 ± 20.6 68.6 ± 24.3 66.6 ± 25.9 0.785
Mean trough level of tacrolimus at 
discharge (ng/mL) 4.9 ± 2.1 4.5 ± 2.2 4.2 ± 2.0 0.436
Table 2. Index hospitalization parameters. *Seven cases of 19 were mixed rejection (Antibody-mediated 
rejection with T-cell mediated rejection).
Figure 2. Cumulative incidence of early hospital readmission by immunologic group.
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EHR (P = 0.342). In adjusted models, EHR was significantly associated with death-censored graft loss (HR: 2.97, 
95% CI: 1.46–6.04; P = 0.003) but not with mortality (HR: 1.46, 95% CI: 0.32–6.70; P = 0.625).
Mean estimated glomerular filtration rates (eGFR) of the three KT groups were similar for 12 months after 
KT, while patients with EHR had consistently lower eGFR during the same period compared to those without 
EHR (Fig. 4).
Late hospital readmission occurred for 284 patients (n = 181 controls, n = 68 ABOi KTs, and n = 35 of HLAi 
KTs, respectively, P = 0.198). Of patients with EHR, 50% (48/96) were readmitted within 1 year, while only 37.1% 
(236/636) of those without EHR were readmitted within 1 year after transplantation (Fig. 5, P = 0.016). The risk of 
AMR during the late hospital readmission period was not significantly different among the groups (8.9% in HLAi 
KT, 5.7% in ABOi KT, and 4.0% in control groups, P = 0.162).
Cox regression analysis revealed advanced age (≥60 years) and HLAi KT as significant independent risk fac-
tors for EHR (Table 4). History of diabetes and cardiovascular disease, BMI, index hospitalization LOS, and ABOi 
KT status were not significantly associated with EHR.
Controls 
(n = 55)
ABOi KT 
(n = 20)
HLAi KT 
(n = 21)
Infection 17 (30.9%) 6 (30%) 11 (52.4%)
Creatinine elevation 15 (27.3%) 9 (45%) 5 (23.8%)
Surgical complication 7 (12.7%) 1 (5%) 2 (9.5%)
Gastrointestinal tract disorder 6 (10.9%) 1 (5%) 0
Metabolic disorder 2 (3.6%) 1 (5%) 1 (4.8%)
Urologic disorder 2 (3.6%) 0 0
Cardiologic disorder 1 (1.8%) 1 (5%) 0
Others 5 (9.1%) 1 (5%) 2 (9.5%)
Table 3. Causes of early hospital readmission.
Figure 3. Death-censored graft survival by early hospital readmission.
Figure 4. Changes in glomerular filtration rate by early hospital readmission.
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Discussion
In this study, HLAi KT significantly increases the risk of EHR compared to ABOi KT and immunologically com-
patible KT. Additional risk factor for EHR was advanced age. Patients who experienced EHR experienced greater 
risk of late hospital readmission and death-censored graft loss and exhibited consistently lower eGFR compared 
to those without EHR during the first post-operative year.
KT recipients are vulnerable to EHR due to the large burden of comorbidities and lifelong immunosuppres-
sion. Among them, patients with high immunologic risks (ABOi or HLAi KT) receive desensitization and potent 
immunosuppression. Recent multi-center study reported that HLAi KT is associated with increased risk of hos-
pital readmission compared to compatible KT16. Unlike prior studies, we included ABOi KT patients in order to 
evaluate the impact of desensitization to EHR. Interestingly, ABOi KT had a similar risk of EHR compared to 
compatible KT despite desensitization therapy. However, HLAi KT was associated with increased risk of EHR. 
The significantly higher risk of AMR in HLAi KT is a possible explanation for this result. In addition, intensified 
immunosuppressive therapy for AMR may further increase the risk of infectious complications, the most com-
mon cause of EHR in HLAi KT patients21. Our data suggest that the risk of EHR was associated with the high 
immunogenicity of HLAi KT patients, rather than desensitization therapy.
The incidence of EHR in our study (13.1%) was considerably lower than that found in a large population-based 
United States study (31%)7. A recent Canadian population-based study also showed a higher EHR incidence 
(20.7%) than in our patients8; however we analyzed living donor KT patients, who typically have a lower risk for 
EHR. In addition, differences in healthcare systems and LOS across countries could account for variations in EHR 
incidence rates22,23. Because patients in Korea are in the hospital for approximately 2 weeks following KT, adverse 
events occurring during this period can be treated without affecting incidence of EHR. Long LOS is common in 
the Korean medical environment, which has a sufficient number of beds and a national health insurance system24. 
According to OECD reports, the average LOS for all causes in Korea is 2.1 times longer than the OECD average, 
2.6 times longer than the US25.
Similar to prior studies, we found that advanced age is associated with EHR7, as elderly recipients are more 
likely to have comorbidities at the time of KT than younger patients14,26. In addition, older patients are more 
susceptible to infections due to progressive decline in immune function27. Therefore, elderly recipients should be 
managed especially carefully, as they are more vulnerable to adverse events requiring EHR.
Our study extended the previous work on EHR and poor outcomes including late readmission and 
death-censored graft loss. To our knowledge, our study was first to describe the outcomes following EHR in 
incompatible KT patients. McAdams-DeMarco et al. demonstrated that EHR was associated with late readmis-
sion, graft loss, and mortality9. In this study, EHR was associated with an increased risk of late readmission 
Figure 5. Cumulative incidence of late readmission by early hospital readmission.
Variable
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Female 0.891 (0.591, 1.344) 0.581
Immunologic risk
  ABOi KT 1.123 (0.673, 1.874) 0.656 1.118 (0.670, 1.866) 0.669
  HLAi KT 2.414 (1.459, 3.993) 0.001 2.258 (1.352, 3.772) 0.002
History of diabetes 1.184 (0.766, 1.831) 0.447
History of CVD 1.218 (0.564, 2.629) 0.616
Age ≥60 years 1.895 (1.177, 3.051) 0.009 1.933 (1.199, 3.119) 0.007
BMI ≥ 25 kg/m2 1.330 (0.832, 2.125) 0.233
Delayed graft function 2.021 (0.936, 4.364) 0.073 1.723 (0.775, 3.831) 0.182
Biopsy-proven acute rejection* 1.645 (0.828, 3.267) 0.155 1.311 (0.639, 2.691) 0.460
Length of stay (post-KT) 1.004 (0.987, 1.021) 0.657
Table 4. Risk factors for early hospital readmission. *During index hospitalization.
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and death-censored graft loss but not mortality. A noteworthy finding in our study involves the impact of EHR 
on outcomes with respect to immunological compatibility status. In addition, this is the first study to compare 
renal function according to EHR. Although population-based data contain highly accurate information about 
admission, graft failure, and mortality, they lack granular detail about immunologic risk, biopsy results, and renal 
function, which are vital when determining care of KT recipients.
EHR often represents an adverse event, results in increased cost of care, and has become an indicator of 
healthcare quality6. However, emerging evidence suggests that EHR is largely driven by patient characteristics28. 
In the transplant field, immunologic risks exert a meaningful effect on risk of EHR17, and advanced age increases 
risk of readmission because of comorbidities and compromised immunity. Despite the higher risk of EHR, 
incompatible KT continues to demonstrate a significant survival benefit compared with remaining on dialysis5,26. 
Consequently, EHR does not necessarily result from poor quality of care, but rather represents the best possible 
care for these most vulnerable patients16,29.
Our present study has some limitations that warrant consideration. First, our single-center design limits the 
generalizability of this study. However, this made it possible to maintain homogeneity in the desensitization pro-
tocol and immunosuppressive regimen. Second, certain recipient risk factors previously found to be predictors of 
EHR (e.g., frailty, chronic obstructive pulmonary disease) were not included in our analysis, necessitating further 
studies to understand why these patients in particular require hospital readmission.
In conclusion, we found that HLAi KT and advanced age increase the risk of EHR after living donor KT. EHR 
was also associated with inferior renal function, late hospital readmission, and death-censored graft loss. Thus, 
KT recipients who are at risk for EHR should be managed with great care, including monitoring of DSA, renal 
function, and infectious complications.
Methods
Study population. For this retrospective single-center study, we screened 850 adult patients who under-
went living donor KT between 2010 and 2017 at Severance Hospital in Seoul, Korea. Exclusion criteria included 
multi-organ transplantation and use of cyclosporin. Patients were classified as HLAi KT, ABOi KT, or compatible 
KT (no HLA or ABO incompatibility). HLAi KT patients exhibited a positive crossmatch (CDC and/or flow cyto-
metric crossmatch) with detectable anti-HLA donor-specific antibody. Combined HLAi and ABOi transplants 
were classified in the HLAi KT group. Follow-up information was available for patients on death and graft loss 
until October 31, 2018.
Definitions. EHR was defined as at least one readmission to the transplant hospital within 30 days after 
discharge from the index hospitalization7. The primary reason for EHR was ascertained by chart review. Late 
hospital readmission was defined as that occurring during the year after the EHR window9.
Desensitization and immunosuppression. All ABOi or HLAi KTs were performed according to the 
desensitization protocol as described previously30. Briefly, rituximab was administered within 7 days before kid-
ney transplantation in cases of ABOi or HLAi KT. Plasmapheresis was performed until the target antibody titer 
(IgG titer ≤ 1:16 in ABOi KT, negative CDC T-cell crossmatch in HLAi KT) was achieved.
The maintenance immunosuppressive regimen was tacrolimus, prednisolone, and mycophenolate mofetil 
(MMF). MMF was administered 1 week before transplantation in ABOi KT or HLAi KT cases. Some patients 
who experienced recurrent adverse events associated with MMF (gastrointestinal trouble or leukopenia) dis-
continued MMF at the clinician’s discretion. We administered tacrolimus 1 day before or on the day of trans-
plantation in all patients, regardless of immunologic risk. The doses of maintenance immunosuppression were 
administered per institutional protocols.
Postoperative care and renal biopsy. Before index discharge, all patients received comprehensive edu-
cation and clearance from transplant team members. After discharge, patients visited the transplant clinic every 
week for laboratory assessments during the first post-transplant month.
Renal biopsies were performed in cases of acute allograft dysfunction (increased serum creatinine >30% from 
baseline or proteinuria >1 g/day). We did not perform routine protocol biopsies during the study period. All 
acute rejections were biopsy proven and classified into antibody-mediated rejection (AMR) or T-cell mediated 
rejection (TCMR) using the 2015 Banff criteria31. All biopsy specimens were stained for C4d.
Prophylaxis protocol and infection monitoring. All patients received trimethoprim–sulfamethoxa-
zole as Pneumocystis jirovecii pneumonia prophylaxis (3–6 months). Fungal prophylaxis consisted of 4 mL of 
oral nystatin four times daily for 3–6 months. No prophylaxis against cytomegalovirus infection was admin-
istered to any patient. Instead, a preemptive approach was used in high-risk patients (donor-seropositive and 
recipient-seronegative).
Study endpoints. The primary study endpoint was the incidence of EHR. The secondary endpoints included 
causes and risk factors of EHR, late hospital readmission, death-censored graft survival, patient survival, and graft 
function. GFR was estimated using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation32.
Statistical analysis. Data were expressed as frequencies (percentages), means and standard deviations, or 
medians and interquartile ranges, as appropriate. Chi-square or Fisher’s exact tests were used to compare cat-
egorical variables. Continuous variables were compared using one‐way analysis of variance (parametric data) 
with post hoc Bonferroni analysis or Kruskal-Wallis (nonparametric data) with post hoc analysis with Dunn’s 
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correction for multiple comparisons. Graft survival and EHR were analyzed using the Kaplan-Meier curves and 
the log-rank test. Univariate and multivariate analyses were performed using Cox proportional hazard regression 
models to determine risk factors for EHR. Statistical analyses were calculated using SPSS software (version 23.0; 
SPSS Inc., Chicago, IL, USA), and P < 0.05 indicated statistical significance.
Ethics statement. All study procedures were conducted in accordance with the Declaration of Helsinki and 
were approved by the Institutional Review Board of Severance Hospital (4-2018-0716). Informed consent was 
waived by the Institutional Review Board because of the study’s retrospective design.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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